Cabozantinib fails Phase 3 trial

Shares of Exelixis (NASDAQ:EXEL) plummet 49% premarket on light volume in response to the company's disclosure that its prostate cancer drug candidate, cabozantinib, failed to demonstrate a statistically significant increase in overall survival (OS) compared to prednisone. The median OS for the cabozantinib cohort was 11.0 months versus 9.8 months for the prednisone arm (hazard ratio = 0.90; 95% confidence interval; p value = 0.212).

Median progression-free survival (PFS) was 5.5 months for the cabozantinib arm versus 2.8 months for the prednisone arm (hazard ratio = 0.50; 95% confidence ration; p value = 0.0001).

Exelixis will initiate a workforce reduction of ~70% (160 employees) and will take a $6M - 8M restructuring charge.

The clinical development of cabozantinib for metastatic castration-resistant prostate cancer has been deprioritized and the second privotal trial evaluating pain palliation in prostate cancer has been halted.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs